Cathie Wood's been on a shopping spree again, and honestly, it's worth paying attention to what she's picking up in this market. Her Ark funds have had a brutal couple of years, down significantly from those 2021 peaks, so every move matters right now.

Earlier this week Wood added to positions in three names: Guardant Health, Oklo, and CRISPR Therapeutics. Let me break down what's interesting about each one.

Guardant Health is actually one of the few holdings that's worked this cycle. The stock's up solid this year and has basically doubled from its lows. They're doing precision oncology tests, and while they're not profitable yet, their Guardant360 product already has real commercial traction. The numbers are kind of wild when you dig in - they're processing hundreds of thousands of tests annually at around $2,500 a pop with strong margins. They're targeting profitability by 2028 with revenue potentially hitting $2 billion. That's the kind of inflection story Wood tends to hunt for.

Then there's Oklo. This one's been rougher - down year-to-date and still finding its footing as a public company. It's a nuclear recycling play, which fits Wood's clean energy thesis. Sam Altman's involved as chairman, which obviously brings some credibility to the story. They just completed a big milestone with their fuel recycling process, but the market hasn't really reacted yet. It's still early innings here.

CRISPR is the third one, and this is classic Wood territory. Gene editing is still early, but CRISPR got its first FDA approval last year with Casgevy. That's validation that the platform actually works. The stock's down this year, which is exactly when Wood tends to get aggressive on her conviction picks. She clearly sees the risk-reward as skewed in her favor here.

What's interesting is Wood's willingness to keep buying into beaten-down names when she believes in the thesis. Whether it works out this time around is the real question, but you can see the pattern - early-stage biotech, energy innovation, disruptive tech. That's her playbook. If you're following along with what's happening in these spaces, watching where she's deploying capital is usually worth tracking.